Compare ZTS & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTS | WAT |
|---|---|---|
| Founded | 1952 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1B | 33.5B |
| IPO Year | 2012 | 1996 |
| Metric | ZTS | WAT |
|---|---|---|
| Price | $79.82 | $357.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $154.18 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 6.3M | 812.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | ★ 10.05 | 0.47 |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $9,467,000,000.00 | N/A |
| Revenue This Year | $5.63 | $104.66 |
| Revenue Next Year | $4.77 | $10.40 |
| P/E Ratio | $56.30 | ★ N/A |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $73.82 | $275.05 |
| 52 Week High | $161.77 | $414.15 |
| Indicator | ZTS | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 52.93 |
| Support Level | $74.35 | $323.66 |
| Resistance Level | $82.34 | $392.00 |
| Average True Range (ATR) | 2.41 | 12.13 |
| MACD | 1.54 | -2.39 |
| Stochastic Oscillator | 58.20 | 40.44 |
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.